



Notice Regarding the Grant Decision for the AMED Public Solicitation "Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy" (Project Title: Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer)

September 17, 2026

1. Overview

As announced in our notice dated July 24, 2026, "Notice Regarding the Acceptance of a Proposal for the AMED Public Solicitation 'Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy' (Project Title: Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer)," our proposal for the "Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer" (hereinafter referred to as the "Project") has been adopted for the public solicitation program "FY2026 Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy" by the Japan Agency for Medical Research and Development (AMED).

We hereby announce that we have received a notice of grant decision from AMED.

2. Subsidized Project Period and Planned Grant Amount

Item	Details
Subsidized Project Period:	September 14, 2026 to March 31, 2027
Planned Grant Amount for FY2026:	JPY 79,993 thousand

Note: The final grant amount and the timing of its recognition will be determined upon receipt of the notice of final determination of the grant amount from AMED.

3. Impact on Financial Results

As the formal determination of the exact grant amount is expected to take place in the next fiscal year, we will promptly announce the details once they are confirmed. Please note that this matter will have no impact on the Company's consolidated financial results for the fiscal year ending March 31, 2027.